Background:The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is controversial. To examine the risk of 10-year cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathological characteristics of very high-risk cT3b/4 PCa patients treated with RP as the primary treatment option.Methods:In a multi-institutional cohort, 266 patients with very high-risk cT3b/4 PCa treated with RP were identified. All patients underwent RP and pelvic lymph-node dissection. Competing-risk analyses assessed 10-year CSM and OCM before and after stratification for age and Charlson comorbidity index (CCI).Results:Overall, 34 (13%) patients died from PCa and 73 (28%) from OCM. ...
INTRODUCTION & OBJECTIVES: The optimal primary treatment for men with clinically high-risk prostate ...
Introduction: Radical prostatectomy (RP) in patients with locally advanced (cT3) prostate cancer (PC...
PURPOSE: Contemporary treatment strategies for localized prostate cancer (PCa) have been evolved ove...
BACKGROUND: The value of radical prostatectomy (RP) as an approach for very high-risk prostate cance...
BACKGROUND The value of radical prostatectomy (RP) as an approach for very high-risk prostate can...
Background: The study aimed to assess predictors and to identify patients at increased risk of prost...
Background: The current role of radical prostatectomy (RP) in patients with high-risk disease remain...
PURPOSE: To assess survival and competing causes of mortality in prostate cancer (PCa) patients ref...
BACKGROUND: There is no consensus on the optimal treatment for localized high-risk prostate cancer (...
Context: The appropriate therapy for men with clinically localized prostate cancer is uncertain. A r...
Background Prostate cancer (PCa) patients with pretreatment prostate-specific antigen (PSA) >20 ng/m...
Introduction & Objectives : High-risk (HR) prostate cancer (PC) is associated with less favourable b...
Background: Current guidelines recommend androgen deprivation therapy only for men with very high-ri...
OBJECTIVE In patients with a long life expectancy with high-risk (HR) prostate cancer (PCa), the ...
Background: There are limited prognostic data for locally advanced prostate cancer PCa to guide in t...
INTRODUCTION & OBJECTIVES: The optimal primary treatment for men with clinically high-risk prostate ...
Introduction: Radical prostatectomy (RP) in patients with locally advanced (cT3) prostate cancer (PC...
PURPOSE: Contemporary treatment strategies for localized prostate cancer (PCa) have been evolved ove...
BACKGROUND: The value of radical prostatectomy (RP) as an approach for very high-risk prostate cance...
BACKGROUND The value of radical prostatectomy (RP) as an approach for very high-risk prostate can...
Background: The study aimed to assess predictors and to identify patients at increased risk of prost...
Background: The current role of radical prostatectomy (RP) in patients with high-risk disease remain...
PURPOSE: To assess survival and competing causes of mortality in prostate cancer (PCa) patients ref...
BACKGROUND: There is no consensus on the optimal treatment for localized high-risk prostate cancer (...
Context: The appropriate therapy for men with clinically localized prostate cancer is uncertain. A r...
Background Prostate cancer (PCa) patients with pretreatment prostate-specific antigen (PSA) >20 ng/m...
Introduction & Objectives : High-risk (HR) prostate cancer (PC) is associated with less favourable b...
Background: Current guidelines recommend androgen deprivation therapy only for men with very high-ri...
OBJECTIVE In patients with a long life expectancy with high-risk (HR) prostate cancer (PCa), the ...
Background: There are limited prognostic data for locally advanced prostate cancer PCa to guide in t...
INTRODUCTION & OBJECTIVES: The optimal primary treatment for men with clinically high-risk prostate ...
Introduction: Radical prostatectomy (RP) in patients with locally advanced (cT3) prostate cancer (PC...
PURPOSE: Contemporary treatment strategies for localized prostate cancer (PCa) have been evolved ove...